Alvotech Prices $152M Equity Offering at $3.75, Matching Report's Attractive Entry

What happened

Alvotech priced a $152 million public offering of 22.7 million shares at $3.75 per share, a 19% discount to the prior close. This offering comes amid ongoing FDA manufacturing deficiencies that forced a guidance cut in November 2025. The DeepValue report had set an attractive entry at $3.75, reflecting the high risk of regulatory and balance sheet stress. While the capital raise provides near-term liquidity, it dilutes existing shareholders by ~7% and underscores the company's urgent need for cash. The timing suggests management is prioritizing funding for AVT05 remediation and working capital over preserving shareholder value.

Implication

The $3.75 pricing aligns with DeepValue's attractive entry, but the offering itself is a negative signal of financial distress. Investors should monitor FY2025 results and AVT05 status; only consider a position after clear remediation progress and sustainable cash generation.

Thesis delta

The offering at the report's attractive entry confirms that management sees the stock as fairly valued at this distressed level, but the dilution and implied cash needs increase the downside if AVT05 remediation fails. This shifts the risk/reward slightly more negative in the near term, as existing holders absorb dilution without immediate operational improvement.